Search research articles
Contact Us
Filters
Showing results (1-10 of 124) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2006
Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma
Ruediger Spitz, Barbara Hero, Thorsten Simon, et al.
Psychometrika
|
November 4, 2020
Network Trees: A Method for Recursively Partitioning Covariance Structures
Payton J Jones, Patrick Mair, Thorsten Simon, et al.
Neurosurgery
|
February 22, 2013
Diagnostic value and safety of stereotactic biopsy for brainstem tumors: a systematic review and meta-analysis of 1480 cases
Philipp Kickingereder, Peter Willeit, Thorsten Simon, et al.
Journal of Pediatric Hematology/Oncology
|
February 7, 2007
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial
Thorsten Simon, Alfred Längler, Frank Berthold, et al.
Journal of Pediatric Hematology/Oncology
|
December 14, 2004
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status
Thorsten Simon, Rüdiger Spitz, Andreas Faldum, et al.
Cancer Letters
|
July 16, 2005
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q
Thorsten Simon, Rüdiger Spitz, Barbara Hero, et al.
Pediatric Blood & Cancer
|
September 27, 2021
Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastoma
Marc Hoemberg, Ruth Schwenzfeur, Frank Berthold, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97
Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Biometrical Journal. Biometrische Zeitschrift
|
October 15, 2024
Confirmatory Adaptive Designs for Clinical Trials With Multiple Time-to-Event Outcomes in Multi-state Markov Models
Moritz Fabian Danzer, Andreas Faldum, Thorsten Simon, et al.
Cancer Research
|
January 20, 2007
Activation of Akt predicts poor outcome in neuroblastoma
Daniela Opel, Christopher Poremba, Thorsten Simon, et al.
Page
of 13
Search research articles
Search
Showing results (1-10 of 124) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2006
Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma
Ruediger Spitz, Barbara Hero, Thorsten Simon, et al.
Psychometrika
|
November 4, 2020
Network Trees: A Method for Recursively Partitioning Covariance Structures
Payton J Jones, Patrick Mair, Thorsten Simon, et al.
Neurosurgery
|
February 22, 2013
Diagnostic value and safety of stereotactic biopsy for brainstem tumors: a systematic review and meta-analysis of 1480 cases
Philipp Kickingereder, Peter Willeit, Thorsten Simon, et al.
Journal of Pediatric Hematology/Oncology
|
February 7, 2007
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial
Thorsten Simon, Alfred Längler, Frank Berthold, et al.
Journal of Pediatric Hematology/Oncology
|
December 14, 2004
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status
Thorsten Simon, Rüdiger Spitz, Andreas Faldum, et al.
Cancer Letters
|
July 16, 2005
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q
Thorsten Simon, Rüdiger Spitz, Barbara Hero, et al.
Pediatric Blood & Cancer
|
September 27, 2021
Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastoma
Marc Hoemberg, Ruth Schwenzfeur, Frank Berthold, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97
Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Biometrical Journal. Biometrische Zeitschrift
|
October 15, 2024
Confirmatory Adaptive Designs for Clinical Trials With Multiple Time-to-Event Outcomes in Multi-state Markov Models
Moritz Fabian Danzer, Andreas Faldum, Thorsten Simon, et al.
Cancer Research
|
January 20, 2007
Activation of Akt predicts poor outcome in neuroblastoma
Daniela Opel, Christopher Poremba, Thorsten Simon, et al.
Page
of 13